---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-033668"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-09-02T23:59:59+00:00"
generated_at: "2026-05-17T08:44:38.314992+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics appoints Robert Gagnon as CFO effective September 2, 2025

## Summary
- Annual base salary of $465,000, eligible for annual bonus up to 45% of base.
- Stock option for 250,000 shares and restricted stock award for 200,000 shares, both vesting over four years.
- Gagnon previously CFO of Remix Therapeutics and Verastem Oncology; has raised over $2B in capital.
- Appointment is part of Opus's advancement of clinical pipeline for inherited retinal diseases.

## SEC filing metadata
- accession: 0001140361-25-033668
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-09-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125033668/0001140361-25-033668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125033668/ef20054946_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-033668
- JSON: https://secwatch.observer/filing/0001140361-25-033668.json
- Plain text: https://secwatch.observer/filing/0001140361-25-033668.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.